Introduction

The present review seeks to highlight important changes in the recently published atrial fibrillation (AF) guidelines of the European Society of Cardiology (ESC) in comparison to previous recommendations, which are summarized as follows: (1)

Key words: atrial fibrillation, anticoagulation, cardioversion, multidisciplinary heart team

Rate and rhythm control

Acute Rate Control

Acute rate control is essential for patients with depressed left ventricular ejection fraction (LVEF <40%) or signs of congestive heart failure (HF) by beta-blockers in the smallest dose necessary to achieve rate control below 110 BPM and/or digoxin or digitoxin. In contrast to previous guidelines, amiodarone is recommended as the last option in patients with severely reduced LV function and/or hemodynamic instability, while verapamil and diltiazem should be avoided due to their negative inotropic effects in patients with pre-existing HF. (1, 2)

Long-term Rate Control

LVEF has been similarly implemented as criterion for the selection of agents for long-term rate control: Beta-blockers and/or digoxin (digitoxin) are recommended in AF patients with a LVEF<40 %, while in patients with a LVEF≥ 40%, beta-blockers, digoxin, verapamil or diltiazem are equally recommended. A heart rate of <110 BPM is the true goal for therapy, since a more difficult to achieve BPM goal of <80 had no positive impact on cardiovascular events. (1)

Acute Rhythm Control

Strategies for pharmacological cardioversion in recent onset AF remained widely unchanged, but the definition of „significant structural heart disease“, a situation in which only IV amiodarone is recommended, has been redefined and now includes severe heart failure with reduced ejection fraction (severe HFrEF) or significant aortic stenosis. Previously referred to as “moderate structural heart disease” now includes coronary artery disease, moderate HFrEF, heart failure with mid-range ejection fraction (LVEF 40-49%), heart failure with preserved ejection fraction and abnormal left ventricular hypertrophy.

Treatment should include either amiodarone or vernakalant. In line with previous recommendations, flecainide, propafenone or vernakalant are recommended, while ibutilide should be considered for cardioversion of new-onset AF in the absence of structural heart disease. (1)

Long-term Rhythm Control

In patients with persistent or long-standing persistent AF, either electrical or pharmacological cardioversion is recommended as part of rhythm control therapy.

In order to avoid antiarrhythmic agents with potential side effects without clear indication, the modified EHRA Symptom Scale should be applied to patients with symptomatic AF. This score differentiates between mild and moderate symptoms and is thought to provide a threshold for therapeutic decisions, a hypothesis that requires further prospective validation. In patients without structural heart disease, the use of flecainide, propafenone, dronedarone and sotalol are recommended for long-term rhythm control after careful evaluation of pro-arrhythmic risk. The decision tree in patients with underlying heart disease but without HF has been simplified and includes coronary artery disease, significant valvular heart disease and abnormal left ventricular hypertrophy. In these situations, dronedarone, sotalol and amiodarone (second-line due to extra-cardiac side-effects) are recommended. First-line treatment with amiodarone is recommended in patients with heart failure. (1)

Invasive Rhythm Control

The new guidelines propose the organization of a Heart Team for AF consisting of cardiologists, interventional electrophysiologists and surgeons for decision making. Catheter ablation should be considered as first-line strategy alternatively to antiarrhythmic drug therapy in symptomatic patients with recurrent paroxysmal AF.

Concomitant (biatrial) maze surgery should be considered in symptomatic patients undergoing open heart surgery, but may afford additional pace maker implantation more frequently than catheter ablation. (1)

Management of Precipitating Risk Factors

Precipitating risk factors for the development of AF, such as diabetes, obesity, hypertension, HF and coronary artery disease need to be treated and controlled adequately. (1)

Oral anticoagulation

Based on the CHA2DS2-VASc score, oral anticoagulation (OAC) is recommended in male AF patients with a CHA2DS2-VASc score of 2 or more, and female AF patients with a CHA2DS2-VASc score of 3 more, and should be considered in the presence of a single additional stroke risk factor, ie. a score of 1 in men and 2 in women. Patients with mechanical heart valves should receive a vitamin K antagonist (VKA), regardless of estimated stroke risk. (1)

Choice of the Anticoagulant

Due to the beneficial efficacy/safety profile, Non-Vitamin K antagonist oral anticoagulants (NOACs) are now recommended for stroke prevention and preferred over VKA. (1, 3) In principle all four clinically available NOACs (dabigatran, rivaroxaban, apixaban, edoxaban) can be used interchangeably, although certain patient-related characteristics might support the use of a specific NOAC (e.g. dabigatran in patients with high bleeding risk and recurrent falls, as this agent has a specific antidote, see later).

Ban of antiplatelet therapy

Antiplatelet monotherapy is now contraindicated for stroke prevention in patients with non-valvular AF, irrespective of the CHA2DS2-VASc Score, as is platelet inhibition on top of OAC for secondary prevention after stroke or transient ischemic attack (TIA). (1)

Triple or dual antithrombotic therapy in secondary prevention

The strategy for antithrombotic combination therapy (OACs plus one = dual therapy; or plus two antiplatelet agents = triple therapy) in AF patients with acute coronary syndromes (ACS) or after elective coronary stent-implantation is mostly based on expert opinion. Duration of triple therapy consisting of an OAC, acetylsalicylic acid (ASA) and clopidogrel (the P2Y12-inhbitors prasugel an ticagrelor are currently contraindicated together with OAC) should be performed as short as possible (1 month in stable/elective patients, 1-3-6 months depending on the individual bleeding- and atherothrombotic risk in ACS patients), followed by dual therapy consisting of one antiplatelet agent in combination with either a VKA (INR goal 2,0-2,5) or with a NOAC in the lower tested dose (dabigatran 110mg BID, rivaroxaban 15 mg OD, apixaban 2,5 mg BID, edoxaban 30 mg OD), respectively. Six- to 12 months after PCI (or ACS without PCI), OAC monotherapy seems to sufficiently prevent (recurrent) coronary and thromboembolic events. The use of second generation modern drug eluting stents with a very low risk for stent thrombosis has to be preferred over bare metal stents and supports a short antithrombotic triple combination strategy for 1 month only. (4, 5)

Re-initiation of oac after ischemic stroke or tia

After TIA, OAC can be initiated 1 day after the event, if an intracerebral bleeding has been excluded by computer tomography or magnetic resonance imaging. For patients with ischemic stroke, the 3-6-12-day-rule might be applied („Diener’s law“). (1)

Cardioversion under NOACs

Two prospective randomized controlled trials (X-VeRT and ENSURE-AF) and post-hoc analyses of randomized controlled trials investigated the use of NOACs before, during and after cardioversion, as compared to warfarin. All studies confirmed the safety of NOACs in this indication and, although underpowered, suggested similar outcomes in terms of efficacy. (6, 7)

The initiation of either unfractionated heparin or a NOAC should be considered for acute cardioversion in AF or atrial flutter of >48 hours or unknown duration, while NOACs have not been tested for acute cardioversion in patients with recent onset AF < 48 hours. In case of delayed cardioversion, effective OAC for minimum of 3 weeks is recommended, irrespective of the agent used. A transesophageal echocardiography to exclude left trial thrombi is useful in certain indications e.g. if a patient has not received or fully taken the recommended anticoagulation prior to cardioversion. (1)

How to manage severe active bleeding under oral anticoagulants

Besides red blood cell support and local mechanical measures (if applicable), the combination of fresh frozen plasma (FFP) and prothrombin complex concentrates (PCC) has been shown to be helpful in intracerebral bleedings on a VKA. Both activated (e.g. FEIBA®) and non-activated (e.g. Beriplex®) PCCs reverse the anticoagulant effect of NOACs sufficiently and are therefore indicated if specific antidotes are not available. Recently, the humanized antibody idarucizumab, an effective antidote against dabigatran, has been introduced for clinical use in many countries. (8) Moreover, an antidot against FXa-inhibitors and heparins, andexanet alpha, is in phase-3 clinical testing. (9)

References

  1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37(38):2893-2962.
  2. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991;83(1):52-60.
  3. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383(9921):955-62.
  4. Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrie D, Naber C, Lipiecki J, Richardt G, Iniguez A, Brunel P, Valdes-Chavarri M, Garot P, Talwar S, Berland J, Abdellaoui M, Eberli F, Oldroyd K, Zambahari R, Gregson J, Greene S, Stoll HP, Morice MC, Investigators LF. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. N Engl J Med 2015;373(21):2038-47.
  5. Valgimigli M, Patialiakas A, Thury A, McFadden E, Colangelo S, Campo G, Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga E, Testa L, Gabriel HM, Airoldi F, Ferlini M, Liistro F, Dellavalle A, Vranckx P, Briguori C, Investigators Z. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol 2015;65(8):805-15.
  6. Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri MF, Grosso MA, Fernandez V, Al-Saady N, Pelekh N, Merkely B, Zenin S, Kushnir M, Spinar J, Batushkin V, de Groot JR, Lip GY. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 2016.
  7. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, Scanavacca M, Vardas PE, Kirchhof P, Hemmrich M, Lanius V, Meng IL, Wildgoose P, van Eickels M, Hohnloser SH, Investigators XV. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014;35(47):3346-55.
  8. Pollack CV, Jr., Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015;373(6):511-20.
  9. Connolly SJ, Milling TJ, Jr., Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M, Investigators A-. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. N Engl J Med 2016.

Miklos Rohla, Kurt Huber
3rd Medical Department, Cardiology, Intensive Care Medicine, and Chest Pain Unit, Wilhelminenhospital, Vienna, Austria
Sigmund Freud University, Medical School, Vienna, Austria

Corresponding author:
Miklos Rohla, MD
3rd Medical Department, Cardiology and Intensive Care Medicine
Wilhelminenhospital, Montleartstraße 37,
1160 Vienna, Austria
Phone: 00 43 1 49150 2301
Fax: 00 43 1 49150 2309
E-mail: miklos.rohla@meduniwien.ac.at

Creative Commons LicenseThis work is licensed under a Creative Commons Attribution 4.0 International License